Analysis of how to safely discontinue Sunitinib (Sutent) and the risk of discontinuation

Sunitinib is an oral multi-target tyrosine kinase inhibitor commonly used to treat malignant tumors such as renal cell carcinoma and gastrointestinal stromal tumors. Since its mechanism of action involves inhibiting tumor growth and angiogenesis, long-term administration is often required in clinical applications. However, under certain circumstances, such as when the patient experiences severe adverse reactions, is in remission, or needs to change the treatment plan, the doctor may recommend discontinuation of the drug. It should be emphasized that the discontinuation of sunitinib must be done under the guidance of a doctor and cannot be interrupted on your own to avoid unnecessary risks.

The condition and adverse reactions should be evaluated before discontinuing medication. Some patients may experience high blood pressure, abnormal heart function, liver function damage or severe fatigue reactions during medication. If these adverse reactions exceed the tolerable range, the doctor will take into account the patient's condition control and the severity of the side effects to decide whether to temporarily reduce the dosage, discontinue the medication, or ultimately discontinue the medication. Stopping medication hastily may lead to rapid tumor progression or changes in drug resistance mechanisms, thus affecting long-term efficacy.

Risks after discontinuation mainly include disease recurrence and progression. Sunitinib delays the progression of the disease by inhibiting the blood supply to the tumor. Once the drug is discontinued, the tumor may return to an active state, with the risk of rapid growth and even metastasis. Particularly in patients whose disease is still active, the risk of sudden discontinuation is higher. Therefore, "dose reduction" or "intermittent discontinuation" strategies are often used in clinical practice, rather than completely discontinuing the drug at once, to reduce the possibility of recurrence and progression while giving the body a certain amount of time to recover.

Patients require strict follow-up and monitoring after discontinuation of medication. After stopping the drug, regular imaging examinations (such as CT, MRI) as well as liver and kidney function, blood pressure and heart monitoring are usually required to detect changes in the condition in a timely manner. If the disease progresses, doctors will consider restarting sunitinib or switching to other targeted drugs or immunotherapy regimens. In addition, patients still need to pay attention to lifestyle management during the drug withdrawal period, such as maintaining a healthy diet, regular work and rest, and controlling blood pressure, to assist the body in recovery and reduce the risk of recurrence. In short, the discontinuation of sunitinib must follow doctor's guidance, scientific evaluation and continuous monitoring, so as to minimize potential risks while ensuring the therapeutic effect.

Reference materials:https://www.drugs.com/